Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 1Phase 2 Interventional

Bronchial NIR Image-guided Resection

NCT03097575
Conditions
Sentinel Lymph Node
Interventions
ICG Intervention, Near Infrared Imaging
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions
Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
Procedure · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Malignant Brain Tumors, Glioma
Interventions
SBK2-ICG, Craniotomy (Standard of Care)
Drug · Procedure
Lead sponsor
Tiffany Hodges
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio • Dayton, Ohio
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Melanoma
Interventions
Indocyanine Green, Lymphangiography, Lymphovenous Bypass
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Withdrawn Not applicable Interventional Accepts healthy volunteers

Erythrocyte Ghost Mediated Retinal Diagnosis

NCT02445001
Conditions
Retinal Disease
Interventions
ICG loaded erythrocytes
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
40 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatocellular Carcinoma
Interventions
ICG, Optical molecular imaging
Biological · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer, Lymph Node Mapping, Sentinel Lymph Node Biopsy
Interventions
IC2000 and SPY-PHI, Tc-99m radioactive colloid and Gamma Probe
Combination Product
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 2 more
Conditions
Indocyanine Green (ICG), Robotic Surgical Procedure, Deep Infiltrating Endometriosis (DIE), Endometriosis Pelvic, Endometriosis (Diagnosis), Endometriosis of the Cul-de-sac, Ureteral Stent Placement, Ureteral Injury, Endometriosis Ovaries
Interventions
Indocyanine Green (ICG)-Assisted Ureteral Identification, Standard Ureteral Identification without ICG
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma
Interventions
ICG Intervention
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
High Grade Sarcoma, Sarcoma
Interventions
Electronic Health Record Review, Fluorescence Imaging, Fluorescence-Guided Surgery, Indocyanine Green, Questionnaire Administration, Resection
Other · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Conditions
Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
Interventions
NIRSense Tissue Oximetry Sensor System
Device
Lead sponsor
NIRSense Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Weston, Florida
Conditions
Vulvar Cancer
Interventions
ICG guided sentinel lymph node biopsy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Conditions
Endometrial Cancer
Interventions
Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG), Neoprobe Gamma Detection System NPB11L(Model1102)
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Stanford, California
Conditions
Peripheral Vascular Disease
Interventions
SPY Imaging, ICG dye (0.2 - 0.5 mg/kg), SPY Imaging
Device
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
To Assess the Feasibility, Visualization Capability, and Optimal Dosing of ICG Fluorescence Imaging for Intraoperative Assessment of Knee Tissue Perfusion
Interventions
Intravenous administration of indocyanine green (SPY Agent Green) 2 mL of SPY Agent Green (5.0 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 3 mL of SPY Agent Green (7.5 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 4 mL of SPY Agent Green (10 mg dose), Intravenous administration of indocyanine green (SPY Agent Green)5 mL of SPY Agent Green (12.5 mg dose)
Combination Product
Lead sponsor
Henry Ford Health System
Other
Eligibility
14 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Recurrent Melanoma
Interventions
Indocyanine green solution, Isosulfan blue (ISB), Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)
Drug · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Conditions
Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple
Interventions
ICG Intervention, Near Infrared Camera
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cubital Tunnel Syndrome
Interventions
Indocyanine green
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Lymph Node Mapping in Patients With Endometrial Cancer

NCT01818739
Conditions
Endometrial Cancer
Interventions
sentinel lymph node detection, indocyanine green solution, isosulfan blue, sentinel lymph node biopsy
Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Completed No phase listed Observational Results available

ICG 24h Prior to Operative Treatment of Orthopaedic Infection

NCT04927637
Conditions
Trauma Injury, Bone Infection
Interventions
imaging 24 hours following intravenous administration of ICG
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed Early Phase 1 Interventional Accepts healthy volunteers

ICG to Assess Ovarian Perfusion

NCT03927651
Conditions
Fibroid Uterus, Endometriosis, Uterus Myoma, Uterine Fibroid, Uterine Adenomyosis, Endometrial Cyst, Uterine Cyst
Interventions
ICG
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lymphedema, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
technetium Tc 99m sulfur colloid, methylene blue, indocyanine green solution, sentinel lymph node biopsy, axillary lymph node biopsy, bioimpedance spectroscopy, quality-of-life assessment, lymphedema management
Radiation · Drug · Procedure + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis, Lymph Node Mapping, Lymphadenectomy, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Completed Early Phase 1 Interventional Results available

ICG and SLN Mapping

NCT05859971
Conditions
Breast Cancer
Interventions
SLN mapping using technetium-99m +/- isosulfan blue dye, SLN mapping with ICG fluorescence using the Asimov Platform
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin